ATF6 aggravates angiogenesis-osteogenesis coupling during ankylosing spondylitis by mediating FGF2 expression in chondrocytes

Mengjun Ma,Hongyu Li,Peng Wang,Wen Yang,Rujia Mi,Jiahao Zhuang,Yuhang Jiang,Yixuan Lu,Xin Shen,Yanfeng Wu,Huiyong Shen
DOI: https://doi.org/10.1016/j.isci.2021.102791
IF: 5.8
2021-07-01
iScience
Abstract:Although angiogenesis-osteogenesis coupling is important in ankylosing spondylitis (AS), therapeutic agents targeting the vasculature remain elusive. Here, we identified activating transcription factor 6 (ATF6) as an important regulator of angiogenesis in the pathogenesis of AS. First, we found that ATF6 and fibroblast growth factor 2 (FGF2) levels were higher in SKG mice and in cartilage of pateints with AS1. The proangiogenic activity of human chondrocytes was enhanced by the activation of the ATF6-FGF2 axis following 7 days of stimulation with inflammatory factors, e.g., tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ) or interleukin-17 (IL-17). Mechanistically, ATF6 interacted with the <i>FGF2</i> promotor and promoted its transcription. Treatment with the ATF6 inhibitor Ceapin-A7 inhibited angiogenesis <i>in vitro</i> and angiogenesis-osteogenesis coupling <i>in vivo</i>. ATF6 may aggravate angiogenesis-osteogenesis coupling during AS by mediating FGF2 transcription in chondrocytes, implying that ATF6 represents a promising therapeutic target for AS.
multidisciplinary sciences
What problem does this paper attempt to address?